English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  52857302    線上人數 :  529
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"ou d l"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 6-30 / 103 (共5頁)
1 2 3 4 5 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2022-08-19T00:20:43Z Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression Ou D.-L.; Cheng A.-L.; Shao Y.-Y.; Feng Z.-R.; Lin L.-I.; Cheng Y.-C.; CHIUN HSU
臺大學術典藏 2022-08-19T00:20:40Z Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy CHIUN HSU; Ou D.-L.; Cheng A.-L.; Chen C.-W.; Tan C.-T.; Lin Y.-Y.
臺大學術典藏 2022-08-19T00:20:40Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy CHIUN HSU; Wang M.-J.; Cheng A.-L.; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.
臺大學術典藏 2022-08-19T00:20:38Z Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma Hsu P.-N.; Cheng A.-L.; CHIUN HSU; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu C.-L.; Lin Y.-Y.; Ou D.-L.
臺大學術典藏 2022-08-19T00:20:30Z Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; Cheng A.-L.; Yang M.-H.; CHIUN HSU
臺大學術典藏 2022-08-19T00:20:25Z Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer Jian C.-Z.; Ou P.-Y.; Ou D.-L.; Hsieh C.-H.; Lin L.-I.; Low G.-S.; CHIUN HSU
臺大學術典藏 2022-08-19T00:20:23Z Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma Shao Y.-Y.; Lin L.-I.; Ling A.; CHIUN HSU; Chen P.-S.; Lee B.-S.; Cheng A.-L.; Ou D.-L.
臺大學術典藏 2022-06-10T06:11:04Z Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:10:59Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏 2022-03-29T07:00:05Z Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma Shen Y.-C.; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; CHING-YU LIN; Liu S.-H.; Cheng A.-L.
臺大學術典藏 2022-03-10T07:58:45Z KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; LI-HUI TSENG; Chang Y.-L.; Yeh K.-H.; Cheng A.-L.
臺大學術典藏 2022-03-04T06:53:38Z Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy Lin Y.-Y.; CHING-TING TAN; Chen C.-W.; Ou D.-L.; Cheng A.-L.; Hsu C.
臺大學術典藏 2022-02-21T02:04:36Z Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG; Yang M.-H.; Hsu C.
臺大學術典藏 2022-02-21T02:04:35Z Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG; Jeng Y.-M.; Hsu C.
臺大學術典藏 2022-02-14T07:10:49Z Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; YUNG-MING JENG; Hsu C.
臺大學術典藏 2022-02-08T07:49:40Z Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer Ou D.-L.; SJ TSENG; Kempson I.M.; Hsu C.-L.; Yang P.-C.; Liao Z.-X.
臺大學術典藏 2022-01-24T06:05:32Z Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer Hsieh C.-H.; Jian C.-Z.; Lin L.-I.; Low G.-S.; Ou P.-Y.; CHIUN HSU; Ou D.-L.
臺大學術典藏 2022-01-12T07:07:41Z CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia Lin T.-C.; HSIN-AN HOU; Chou W.-C.; Ou D.-L.; Yu S.-L.; Tien H.-F.; Lin L.-I.
臺大學術典藏 2022-01-12T07:07:25Z Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD) Lu J.-W.; Wang A.-N.; Liao H.-A.; Chen C.-Y.; HSIN-AN HOU; Hu C.-Y.; Tien H.-F.; Ou D.-L.; Lin L.-I.
臺大學術典藏 2022-01-12T07:07:10Z Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias Su K.-W.; Ou D.-L.; Fu Y.-H.; Tien H.-F.; HSIN-AN HOU; Lin L.-I.
國立成功大學 2022 Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma Shao, Y.-Y.;Chen, P.-S.;Lin, Lin L.-I.;Lee, B.-S.;Ling, A.;Cheng, A.-L.;Hsu, C.;Ou, D.-L.
臺大學術典藏 2021-09-15T01:20:53Z Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma Ou D.-L.; Lin Y.-Y.; CHIA-LANG HSU; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; Cheng A.-L.; Hsu C.
臺大學術典藏 2021-09-15T01:20:46Z Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages Ou D.-L.; Chen C.-W.; CHIA-LANG HSU; Chung C.-H.; Feng Z.-R.; Lee B.-S.; Cheng A.-L.; Yang M.-H.; Hsu C.
臺大學術典藏 2021-09-15T01:20:45Z Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma CHIA-LANG HSU; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; Jeng Y.-M.; Hsu C.
臺大學術典藏 2021-09-15T01:20:45Z Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer Ou D.-L.; Tseng S.-J.; Kempson I.M.; CHIA-LANG HSU; Yang P.-C.; Liao Z.-X.

顯示項目 6-30 / 103 (共5頁)
1 2 3 4 5 > >>
每頁顯示[10|25|50]項目